Renaissance Technologies
FTH

Renaissance Technologies’s Faeth Therapeutics FTH Stock Holding History

Renaissance Technologies’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Buy
32,041
+20,525
+178% +$410K ﹤0.01% 2274
2025
Q4 		$123K Buy
11,516
+1,100
+11% +$10.6K ﹤0.01% 2975
2025
Q3 		$98.4K Buy
+10,416
New +$86.4K ﹤0.01% 3253
2025
Q2 		– Sell
-8,865
Closed -$69.9K – 3872
2025
Q1 		$69.9K Buy
8,865
+1,025
+13% +$9.75K ﹤0.01% 3242
2024
Q4 		$76.8K Sell
7,840
-2,939
-27% -$29.5K ﹤0.01% 3322
2024
Q3 		$129K Sell
10,779
-410
-4% -$5K ﹤0.01% 3214
2024
Q2 		$139K Buy
11,189
+639
+6% +$13.3K ﹤0.01% 3121
2024
Q1 		$222K Buy
10,550
+3,375
+47% +$58.2K ﹤0.01% 3193
2023
Q4 		$99K Buy
7,175
+2,985
+71% +$40.7K ﹤0.01% 3302
2023
Q3 		$67K Sell
4,190
-285
-6% -$6.12K ﹤0.01% 3338
2023
Q2 		$102K Sell
4,475
-1,785
-29% -$52.3K ﹤0.01% 3465
2023
Q1 		$188K Sell
6,260
-2,368
-27% -$70.2K ﹤0.01% 3299
2022
Q4 		$257K Sell
8,628
-1,662
-16% -$48.9K ﹤0.01% 3304
2022
Q3 		$319K Sell
10,290
-2,060
-17% -$81K ﹤0.01% 3184
2022
Q2 		$561K Buy
12,350
+8,190
+197% +$307K ﹤0.01% 3097
2022
Q1 		$192K Buy
+4,160
New +$331K ﹤0.01% 3661

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Renaissance Technologies's FTH Position: Q1 2026 in Review

Renaissance Technologies increased its Faeth Therapeutics (FTH) stake by 178% in Q1 2026, buying an estimated $410K and bringing the position to 32,041 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2274.

Renaissance Technologies first reported a position in FTH in Q1 2022 and has held it in 16 quarters since. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • Renaissance Technologies held 32,041 shares of Faeth Therapeutics worth $1.01M as of Q1 2026.
  • Renaissance Technologies bought 20,525 Faeth Therapeutics shares in Q1 2026, an estimated $410K.
  • Faeth Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2274 holding.
  • Renaissance Technologies first reported a position in Faeth Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.